From Nasdaq.: 2025-02-17 02:12:23

GSK plc has received FDA approval for Penmenvy, a vaccine targeting five major serogroups of Neisseria meningitidis. The vaccine is approved for individuals aged 10 through 25 years and combines components from GSK’s Bexsero and Menveo vaccines.

The CDC’s Advisory Committee on Immunization Practices is set to vote on guidelines for the recommended use of GSK’s MenABCWY vaccine in adolescents and young adults at their meeting on February 26, 2025. Stay updated on health news at rttnews.com.



Read more at Nasdaq.: FDA Approves GSK’s Penmenvy, 5-in-1 Meningococcal Vaccine For MenABCWY Protection